OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of “Hold” from Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) has earned an average rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $6.3333.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research note on Tuesday, April 21st.

Hedge Funds Weigh In On OKYO Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OKYO. Citadel Advisors LLC acquired a new position in OKYO Pharma in the third quarter valued at approximately $31,000. Renaissance Technologies LLC boosted its holdings in OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after purchasing an additional 96,800 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in OKYO Pharma in the fourth quarter valued at approximately $36,000. 2.97% of the stock is owned by institutional investors and hedge funds.

OKYO Pharma Stock Down 1.9%

OKYO stock opened at $1.52 on Thursday. The business’s 50-day moving average is $1.60 and its two-hundred day moving average is $1.80. OKYO Pharma has a 1 year low of $1.42 and a 1 year high of $3.35.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.